Affimed N.V. announced the establishment of a Scientific Advisory Board (SAB) of renowned experts in their respective fields to provide scientific and clinical guidance on the development of Affimed's innate cell engagers (ICE®) programs. This newly formed advisory board includes the following scientific and clinical experts: Stephen M. Ansell, MD, PhD, Professor of Medicine, Division of Hematology at the Mayo Clinic, with extensive expertise in B-cell malignancies, including both Hodgkin and non-Hodgkin lymphomas. Todd A. Fehniger, MD, PhD, Professor of Medicine, Washington University School of Medicine, an internationally recognized leader in natural killer (NK) cell immunotherapy, stem cell transplantation and lymphomas. Prof. Dr. Ulrike Köhl, Professor of Immuno-Oncology, University of Leipzig, director of the Fraunhofer Institute for Cell Therapy and Immunology, Leipzig as well as director of the Institute of Cellular Therapeutics, Hannover Medical School, Germany, a leading expert in the development and manufacturing of cell and gene therapies in cancer with a special focus on NK cells.

Sandro Matosevic, PhD, Assistant Professor, College of Pharmacy at Purdue University, with expertise in the development and use of natural killer cells in cancer treatment, with various patents on the engineering and utilization of NK cells in cancer immunotherapy and solid tumors.